Ani Pharmaceuticals (ANIP) Enterprise Value (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Enterprise Value data on file, last reported at -$311.2 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 107.7% year-over-year to -$311.2 million; the trailing twelve-month figure through Mar 2026 stood at -$311.2 million (down 107.7% YoY), and the FY2025 full-year result was -$285.6 million, down 97.12% from the prior year.
• Enterprise Value slipped to -$311.2 million in Q1 2026, from -$285.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$53.2 million in Q4 2022 to a low of -$311.2 million in Q1 2026.
• A 5-year average of -$170.2 million and a median of -$161.7 million in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value jumped 49.45% in 2022 and slumped 315.38% in 2023, its largest moves.
• Tracing ANIP's Enterprise Value over 5 years: stood at -$53.2 million in 2022, then tumbled by 315.38% to -$221.1 million in 2023, then soared by 34.47% to -$144.9 million in 2024, then sank by 97.12% to -$285.6 million in 2025, then slipped by 8.96% to -$311.2 million in 2026.
• Business Quant data shows ANIP's Enterprise Value at -$311.2 million in Q1 2026, -$285.6 million in Q4 2025, and -$262.6 million in Q3 2025.